Corporate News

From October 10th to 11th, 2025, the 2025 Academic Annual Conference of Laboratory Medicine of the Laboratory Medicine Professional Committee of Beijing Society of Integrated Traditional Chinese and Western Medicine was successfully held in Beijing. This conference brought together top experts and scholars in the field of laboratory medicine in China. They engaged in in-depth exchanges on new laboratory technologies, clinical applications, and multi-disciplinary research. They also conducted in-depth discussions on topics such as blood lipid and chronic disease management, as well as the clinical application of new technologies. The academic atmosphere on the spot was very strong.

Professor Zhang Guojun's special lecture

At the Lipid and Chronic Disease Forum, Professor Zhang Guojun from Beijing Tiantan Hospital, Capital Medical University, delivered a special speech titled "Multi-Center Research Ideas and Results Sharing on the Relationship between Oxidized Low-density Lipoprotein and Cerebrovascular Diseases", which became the focus of the entire event. Professor Zhang systematically expounded the pathological mechanism of oxidized low-density lipoprotein (OxLDL) as a key biomarker of atherosclerosis and its core role in the occurrence and development of cerebrovascular diseases. He pointed out that OxLDL not only participates in vascular endothelial injury and inflammatory responses, but is also closely related to the pathological processes of diseases such as cerebral infarction and transient ischemic attack.

Through in-depth interpretation of large-scale multi-center research data, Professor Zhang's team verified that there is a significant correlation between OxLDL levels and the prognosis and recurrence risk of patients, fully demonstrating its important value in clinical risk assessment, early diagnosis, and efficacy monitoring, providing a solid evidence-based basis for the promotion and application of this marker. In addition, he made a forward-looking outlook on the clinical transformation path of OxLDL research, building a solid academic bridge for promoting this indicator from scientific research to routine testing and ultimately achieving precise prevention and treatment of cerebrovascular diseases.

As a promoter of the detection of oxidized low-density lipoprotein (OxLDL) in the field of prevention and control of cardiovascular and cerebrovascular diseases, Jinci Biotechnology has been deeply involved in the construction of industry technical standards. The group standard "Oxidized Low-density Lipoprotein Detection Kit (Immunoturbidimetric Method)" (T/CSBME 091-2025), drafted by our company, has been officially implemented since August 1, 2025. The company has been deeply engaged in the research and development of technology in this field. Its products are based on its exclusive patented antibody (4E6) and multi-method detection system, which can accurately identify the concentration changes of OxLDL in serum. They have the advantages of high sensitivity, good repeatability and strong anti-interference performance, and can be widely adapted to various clinical automated detection platforms, providing stable and reliable detection support for medical institutions and research units.

In the future, Jinci Biotech will continue to focus on the field of major chronic diseases, concentrating on the research and innovation of early screening and risk prevention and control products. It will join hands with clinical experts to jointly promote the clinical popularization of new markers such as OxLDL and contribute "Jinci strength" to the construction of "Healthy China".